- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05557240
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
Clinical Study on the Effect of Neoantigens on the Therapeutic Efficacy and Intestinal Microbiota in Patients With Newly Diagnosed Glioma
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a signelcenter, open-label, single arm, first-in-human phase I trial to investigate the safety, feasibility and immune response of the novel NeoPep Vaccine in patients with newly diagnosed GB.
Primary Endpoints:
Determine the safety and tolerability profile of NeoPep Vaccine1and 2 when administered with immunomodulators and Stupp standard treatment
Secondry Endpoints:
- Descriptive analysis of induced T-cell immune responses after vaccinations with NeoPep Vaccine1and 2 drug products plus immunomodulators and Stupp standard treatment.
- Overall survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp.
- Progression-free survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp.
After the standard chemoradiotherapy with TMZ has been completed, Vaccination was initiated 14 days before the first maintenanceTMZ cycle. It starts with the first NeoPep Vaccine1, followed by additional NeoPep Vaccine2 at a later time point and ends with the Last Endpoint Evaluation Visit (LEEV) of a patient.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lei Li, Phd
- Phone Number: 18817952194
- Email: Lei-Li@alumni.tongji.edu.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Recruiting
- Shanghai 10th People's Hospital
-
Contact:
- Liang Gao, Phd
- Phone Number: 13817934652
- Email: lianggaoh@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability of subject to understand and the willingness to sign written informed consent for study participation;
- Patients with newly diagnosed high-grade glioma confirmed by histopathological and imaging evaluation;
- Gross total resection (as defined by less than 1 cm2 residual tumor mass on the largest perpendicular axes in post-operative scan taken within 48 h post-surgery; standard MRI conformable to the present national and international guidelines is sufficient);
- At least 0.5 g tumor tissue freshly cryopreserved during surgery,and could provide adequate amounts of PBMC;
- Patient is a candidate for and willing to receive standard CRT with TMZ followed by maintenance TMZ cycles;
- Age 18-70;
- Life expectancy > 9 months;
- KPS≥70;
- Sufficient tumor tissue samples and peripheral blood samples can be obtained for sequencing analysis, or whole exome sequencing and RNA sequencing of tumor tissue samples and peripheral blood samples have been obtained, and the sequencing data meet the prediction requirements;
- Consent of women and men of reproductive age to use adequate and effective contraception during clinical trials;
Normal laboratory values for hematology, liver and renal function (serum creatinine).In detail the following values apply as inclusion criteria:
- White blood cell count (WBC) ≥3.0×109/L;
- Absolutely neutrophil count≥1.0×109/L;
- Platelet count≥80×109/L;
- Hemoglobin content≥90g/L;
- Serum creatinine≤1.5 ULN or Creatinine clearance rate≥40 mL/min;
- TBil(total bilirubin)≤1.5 x ULN;
- Aspartic transaminase(AST)≤2.5x ULN or Alanine aminotransferase(ALT)≤2.5x ULN;Patients with liver metastases must have ≤5x ULN;
- Blood coagulation function :INR≤1.5x ULN;pT and APTT≤1.5x ULN;
- Urine protein< 2 +;if Urine protein≥2+,24-hour urinary protein must be less than 1g.
Exclusion Criteria:
- Patients treated with immunosuppressive agents (e.g., cyclosporin CsA, tacrolimus, rapamycin, azathioprine, etc.) within the previous month; Other immunotherapy within 3 months;
- History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 5 years unless the patient has been disease-free for 5 years;
- Participated in other clinical trials within 30 days prior to screening;
- Have a history of severe allergy or allergic constitution;
- Patients who have undergone splenectomy;
- Persons with primary or secondary immunodeficiency diseases (e.g. AIDS);Patients with autoimmune diseases;
- Patients who received multiple oral, intramuscular, or intravenous corticosteroids within 30 days before the first dose; However, patients who received a single oral, intramuscular, or intravenous dose of dexamethasone of 5mg or less (or another hormone of equivalent potency) 14 days before the first dose were allowed; Allow inhaled corticosteroids to treat respiratory insufficiency (e.g., chronic obstructive pulmonary disease), or topical steroids;
- Patients with uncontrollable seizures, central nervous system disorders, or psychotic loss of cognition;
- Uncontrolled central nervous system metastases;
- Patients had a history of chronic alcohol or drug abuse in the 6 months before screening;
- With unstable systemic disease, such as active infection, liver cirrhosis, chronic renal failure, severe chronic pulmonary disease, unstable hypertension, unstable angina pectoris, congestive heart failure, myocardial infarction within one year, etc. ;
- According to this procedure, the number of candidate neoantigens that can be used to make personalized vaccines is less than 20;
- The investigator did not consider it appropriate to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NeoPep Vaccine1and 2 plus polyICLC concurrent to TMZ
|
NPVAC1: NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse, NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used. Poly-ICLC: Poly-ICLC(500ug)will be used as immunomodulator with all vaccinations.
Other Names:
NPVAC2: NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used. Poly-ICLC: Poly-ICLC(500ug)will be used as immunomodulator with all vaccinations.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and toleration
Time Frame: Continously for about 40 weeks plus follow-up
|
Determine the safety and tolerability profile of NeoPep Vaccine1and 2 when administered with immunomodulators and Stupp standard treatment
|
Continously for about 40 weeks plus follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
T-cell immune response
Time Frame: till 24 months of vaccination
|
Descriptive analysis of induced T-cell immune responses after vaccinations with NeoPep Vaccine1and 2 drug products plus immunomodulators and Stupp standard treatment.
|
till 24 months of vaccination
|
Overall survival(OS)
Time Frame: till 24 months of vaccination
|
Overall survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp.
|
till 24 months of vaccination
|
Progression-free survival(PFS)
Time Frame: till 12 months of vaccination
|
Progression-free survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp.
|
till 12 months of vaccination
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Liang Gao, Phd, Shanghai 10th People's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Immunologic Factors
- Gastrointestinal Agents
- Interferon Inducers
- Laxatives
- Vaccines
- Poly ICLC
- Carboxymethylcellulose Sodium
- Poly I-C
Other Study ID Numbers
- 10247 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma, Malignant
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Henry FriedmanCompletedGrade IV Malignant GliomaUnited States
-
Annick DesjardinsAmgenTerminated
-
Kentuckiana Cancer InstituteEisai Inc.UnknownNewly Diagnosed Supratentorial Malignant GliomaUnited States
-
AmgenCompletedGlioblastoma or Malignant GliomaUnited States, Australia, Netherlands, Germany, Spain, France
-
Duke UniversityMonteris MedicalWithdrawnGlioblastoma | Malignant Glioma of BrainUnited States
-
CellabMEDRecruitingRecurrent Malignant GliomaKorea, Republic of
-
University of ChicagoRecruitingMalignant Glioma of BrainUnited States
-
Angiochem IncCompletedRecurrent or Progressive Malignant GliomaUnited States
Clinical Trials on NeoPep Vaccine1 plus Poly-ICLC
-
Immatics Biotechnologies GmbHBioNTech SE; University Hospital Tuebingen; BCN Peptides; EU-funded GAPVAC ConsortiumCompletedGlioblastomaSpain, Switzerland, Denmark, Germany, Netherlands
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Smallpox | Ebola | Severe Acute Respiratory Distress Syndrome | Unknown Respiratory VirusesUnited States
-
Rockefeller UniversityCompletedHealthy VolunteersUnited States
-
Nina BhardwajNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsCompletedHIV-1 Infected Adults With Chronic HIV-1 InfectionUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
-
Nevada Cancer InstituteCLL TopicsTerminatedB Cell Lymphoma | T Cell LymphomaUnited States
-
Ashutosh Kumar TewariOncovir, Inc.Completed
-
Robert SchoenNational Cancer Institute (NCI)CompletedStudy of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal AdenomaRisk for Colorectal CancerUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Nina BhardwajOncovir, Inc.TerminatedMelanoma | Breast Cancer | Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Skin | Sarcoma of the Skin | Basal Cell Cancer of the SkinUnited States